Activation of GPER ameliorates experimental pulmonary hypertension in male rats

European Journal of Pharmaceutical Sciences

Volumn 97, Issue , 2017, Pages 208-217

  Alencar, Allan K ^a   Montes, Guilherme C ^a   Montagnoli, Tadeu ^a   Silva, Ananssa M ^a   Martinez, Sabrina T ^a   Fraga, Aline G ^a   Wang, Hao ^b   Groban, Leanne ^b   Sudo, Roberto T ^a   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

GPER; Monocrotaline; Right ventricular dysfunction; Vascular remodeling

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIUM; CALCIUM ION; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MONOCROTALINE; PHOSPHOLAMBAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; GPR30 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CARDIOPULMONARY FUNCTION; CARDIOPULMONARY HEMODYNAMICS; CARDITIS; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME ACTIVATION; EXERCISE; EXPERIMENTAL PULMONARY HYPERTENSION; HEART FIBROBLAST; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG FIBROBLAST; LUNG HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR REMODELING; AGONISTS; ANIMAL; DIAGNOSTIC IMAGING; HYPERTENSION, PULMONARY; METABOLISM; RANDOMIZATION; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HYPERTENSION, PULMONARY; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85000623944     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.11.009     Document Type: Article

References (65)

1. Alencar, A.K., da Silva, J.S., Lin, M., Silva, A.M., Sun, X., Ferrario, C.M., Cheng, C., Sudo, R.T., Zapata-Sudo, G., Wang, H., Groban, L., Effect of Age, Estrogen Status, and Late-life GPER Activation on Cardiac Structure and Function in the Fischer344 × Brown Norway Female Rat. 2016 (J Gerontol A Biol Sci Med Sci).
2. Alencar, A.K., Pereira, S.L., da Silva, F.E., Mendes, L.V., Cunha Vdo, M., Lima, L.M., Montagnoli, T.L., Caruso-Neves, C., Ferraz, E.B., Tesch, R., Nascimento, J.H., Sant'anna, C.M., Fraga, C.A., Barreiro, E.J., Sudo, R.T., Zapata-Sudo, G., N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. Int. J. Cardiol. 173 (2014), 154–162.
3. Alencar, A.K., Pereira, S.L., Montagnoli, T.L., Maia, R.C., Kummerle, A.E., Landgraf, S.S., Caruso-Neves, C., Ferraz, E.B., Tesch, R., Nascimento, J.H., de Sant'Anna, C.M., Fraga, C.A., Barreiro, E.J., Sudo, R.T., Zapata-Sudo, G., Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats. Br. J. Pharmacol. 169 (2013), 953–962.
4. Ariazi, E.A., Brailoiu, E., Yerrum, S., Shupp, H.A., Slifker, M.J., Cunliffe, H.E., Black, M.A., Donato, A.L., Arterburn, J.B., Oprea, T.I., Prossnitz, E.R., Dun, N.J., Jordan, V.C., The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 70 (2010), 1184–1194.
5. Asp, M.L., Martindale, J.J., Metzger, J.M., Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling. PLoS One, 8, 2013, e78768.
6. Babiker, F.A., De Windt, L.J., van Eickels, M., Grohe, C., Meyer, R., Doevendans, P.A., Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc. Res. 53 (2002), 709–719.
7. Badiani, B., Messori, A., Targeted treatments for pulmonary arterial hypertension: interpreting outcomes by network meta-analysis. Heart Lung Circ. 25 (2016), 46–52.
8. Bologa, C.G., Revankar, C.M., Young, S.M., Edwards, B.S., Arterburn, J.B., Kiselyov, A.S., Parker, M.A., Tkachenko, S.E., Savchuck, N.P., Sklar, L.A., Oprea, T.I., Prossnitz, E.R., Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2 (2006), 207–212.
9. Borbely, A., van der Velden, J., Papp, Z., Bronzwaer, J.G., Edes, I., Stienen, G.J., Paulus, W.J., Cardiomyocyte stiffness in diastolic heart failure. Circulation 111 (2005), 774–781.
10. Brailoiu, G.C., Arterburn, J.B., Oprea, T.I., Chitravanshi, V.C., Brailoiu, E., Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguus. Exp. Physiol. 98 (2013), 679–691.
11. Carmeci, C., Thompson, D.A., Ring, H.Z., Francke, U., Weigel, R.J., Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45 (1997), 607–617.
12. Consoli, C., Gatta, L., Iellamo, F., Molinari, F., Rosano, G.M., Marlier, L.N., Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism. Int. J. Cardiol. 167 (2013), 2859–2866.
13. Dennis, M.K., Field, A.S., Burai, R., Ramesh, C., Petrie, W.K., Bologa, C.G., Oprea, T.I., Yamaguchi, Y., Hayashi, S., Sklar, L.A., Hathaway, H.J., Arterburn, J.B., Prossnitz, E.R., Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J. Steroid Biochem. Mol. Biol. 127 (2011), 358–366.
14. Deschamps, A.M., Murphy, E., Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H1806–H1813.
15. Dow, M.L., Kirchhoefer, R.D., Brower, J.F., Rapid identification and estimation of gitoxin in digitoxin and digoxin tablets by TLC. J. Pharm. Sci. 60 (1971), 298–299.
16. Dubey, R.K., Oparil, S., Imthurn, B., Jackson, E.K., Sex hormones and hypertension. Cardiovasc. Res. 53 (2002), 688–708.
17. Feldman, A.M., Combes, A., Wagner, D., Kadakomi, T., Kubota, T., Li, Y.Y., McTiernan, C., The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 35 (2000), 537–544.
18. Filardo, E.J., Quinn, J.A., Bland, K.I., Frackelton, A.R. Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000), 1649–1660.
19. Filardo, E.J., Quinn, J.A., Frackelton, A.R. Jr., Bland, K.I., Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16 (2002), 70–84.
20. Filice, E., Recchia, A.G., Pellegrino, D., Angelone, T., Maggiolini, M., Cerra, M.C., A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J. Physiol. Pharmacol. 60 (2009), 3–10.
21. Fontoura, D., Oliveira-Pinto, J., Tavares-Silva, M., Leite, S., Vasques-Novoa, F., Mendes-Ferreira, P., Lourenco, A.P., Leite-Moreira, A.F., Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension. Rev. Port. Cardiol. 33 (2014), 213–222.
22. Frump, A.L., Goss, K.N., Vayl, A., Albrecht, M., Fisher, A., Tursunova, R., Fierst, J., Whitson, J., Cucci, A.R., Brown, M.B., Lahm, T., Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am. J. Phys. Lung Cell Mol. Phys. 308 (2015), L873–L890.
23. Galie, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A.V., Beghetti, M., Ghofrani, A., Sanchez, M.A.G., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L.A., Trindade, P.T., Zompatori, M., Hoeper, M., 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46 (2015), 903–975 (Eur Respir J 46, 1855–1856).
24. Haas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G.C., Gao, X., Mueller-Guerre, L., Marjon, N.A., Gut, A., Minotti, R., Meyer, M.R., Amann, K., Ammann, E., Perez-Dominguez, A., Genoni, M., Clegg, D.J., Dun, N.J., Resta, T.C., Prossnitz, E.R., Barton, M., Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 104 (2009), 288–291.
25. Han, G., White, R.E., G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease. World J. Cardiol. 6 (2014), 367–375.
26. Holm, A., Baldetorp, B., Olde, B., Leeb-Lundberg, L.M., Nilsson, B.O., The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J. Vasc. Res. 48 (2011), 327–335.
27. Humbert, M., Ghofrani, H.A., The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71 (2016), 73–83.
28. Jessup, J.A., Lindsey, S.H., Wang, H., Chappell, M.C., Groban, L., Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One, 5, 2010, e15433.
29. Jones, J.E., Mendes, L., Rudd, M.A., Russo, G., Loscalzo, J., Zhang, Y.Y., Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am. J. Physiol. Heart Circ. Physiol. 283:1 (2002), H364–H371.
30. Kang, S., Liu, Y., Sun, D., Zhou, C., Liu, A., Xu, C., Hao, Y., Li, D., Yan, C., Sun, H., Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLoS One, 7, 2012, e48185.
31. Koskenvuo, J.W., Mirsky, R., Zhang, Y., Angeli, F.S., Jahn, S., Alastalo, T.P., Schiller, N.B., Boyle, A.J., Chatterjee, K., De Marco, T., Yeghiazarians, Y., A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int. J. Card. Imaging 26 (2010), 509–518.
32. Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Picard, M.H., Roman, M.J., Seward, J., Shanewise, J., Solomon, S., Spencer, K.T., St John Sutton, M., Stewart, W., American Society of Echocardiography's, N, Standards, C., Task Force on Chamber, Q, American College of Cardiology Echocardiography, C, American Heart, A, European Association of Echocardiography, E.S.o.C, Recommendations for chamber quantification. Eur. J. Echocardiogr. 7 (2006), 79–108.
33. Levine, B., Kalman, J., Mayer, L., Fillit, H.M., Packer, M., Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323 (1990), 236–241.
34. Lindsey, S.H., Cohen, J.A., Brosnihan, K.B., Gallagher, P.E., Chappell, M.C., Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150 (2009), 3753–3758.
35. Lindsey, S.H., da Silva, A.S., Silva, M.S., Chappell, M.C., Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E113–E118.
36. Liu, L., Kashyap, S., Murphy, B., Hutson, D.D., Budish, R.A., Trimmer, E.H., Zimmerman, M.A., Trask, A.J., Miller, K.S., Chappell, M.C., Lindsey, S.H., GPER activation ameliorates aortic remodeling induced by salt-sensitive hypertension. Am. J. Physiol. Heart Circ. Physiol. 310 (2016), H953–H961.
37. Lourenco, A.P., Fontoura, D., Henriques-Coelho, T., Leite-Moreira, A.F., Current pathophysiological concepts and management of pulmonary hypertension. Int. J. Cardiol. 155 (2012), 350–361.
38. Mair, K.M., Wright, A.F., Duggan, N., Rowlands, D.J., Hussey, M.J., Roberts, S., Fullerton, J., Nilsen, M., Loughlin, L., Thomas, M., MacLean, M.R., Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 190 (2014), 456–467.
39. Manders, E., Rain, S., Bogaard, H.J., Handoko, M.L., Stienen, G.J., Vonk-Noordegraaf, A., Ottenheijm, C.A., de Man, F.S., The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricle. Eur. Respir. J. 46 (2015), 832–842.
40. Mann, D.L., Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91 (2002), 988–998.
41. McLaughlin, V.V., McGoon, M.D., Pulmonary arterial hypertension. Circulation 114 (2006), 1417–1431.
42. Meyer, M.R., Prossnitz, E.R., Barton, M., The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vasc. Pharmacol. 55 (2011), 17–25.
43. Meyer, M.R., Prossnitz, E.R., Barton, M., GPER/GPR30 and regulation of vascular tone and blood pressure. Immunol. Endocr. Metab. Agents Med. Chem. 11 (2011), 255–261.
44. Neder, J.A., Ramos, R.P., Ota-Arakaki, J.S., Hirai, D.M., D'Arsigny, C.L., O'Donnell, D., Exercise intolerance in pulmonary arterial hypertension. The role of cardiopulmonary exercise testing. Ann. Am. Thorac. Soc. 12 (2015), 604–612.
45. Nishida, M., Hasegawa, Y., Tanida, I., Nakagawa, E., Inaji, H., Ohkita, M., Matsumura, Y., Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats. Eur. J. Pharmacol. 614 (2009), 70–76.
46. Noel, S.D., Keen, K.L., Baumann, D.I., Filardo, E.J., Terasawa, E., Involvement of G protein-coupled receptor 30 (GPR30) in rapid action of estrogen in primate LHRH neurons. Mol. Endocrinol. 23 (2009), 349–359.
47. Peacock, A.J., Murphy, N.F., McMurray, J.J., Caballero, L., Stewart, S., An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30 (2007), 104–109.
48. Pei, Y., Ma, P., Wang, X., Zhang, W., Zhang, X., Zheng, P., Yan, L., Xu, Q., Dai, G., Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur. J. Pharmacol. 666 (2011), 165–172.
49. Sahara, M., Sata, M., Morita, T., Hirata, Y., Nagai, R., Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension. PLoS One, 7, 2012, e33367.
50. Schermuly, R.T., Ghofrani, H.A., Wilkins, M.R., Grimminger, F., Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8 (2011), 443–455.
51. Tofovic, S.P., Jackson, E.K., Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur. Respir. J. 41 (2013), 1465–1466.
52. Tracey, K.J., Vlassara, H., Cerami, A., Cachectin/tumour necrosis factor. Lancet 1 (1989), 1122–1126.
53. van Suylen, R.J., Smits, J.F., Daemen, M.J., Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am. J. Respir. Crit. Care Med. 157 (1998), 1423–1428.
54. Vitali, S.H., Hansmann, G., Rose, C., Fernandez-Gonzalez, A., Scheid, A., Mitsialis, S.A., Kourembanas, S., The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. Pulm Circ 4 (2014), 619–629.
55. Voelkel, N.F., Quaife, R.A., Leinwand, L.A., Barst, R.J., McGoon, M.D., Meldrum, D.R., Dupuis, J., Long, C.S., Rubin, L.J., Smart, F.W., Suzuki, Y.J., Gladwin, M., Denholm, E.M., Gail, D.B., National Heart, L, Blood Institute Working Group on, C, Molecular Mechanisms of Right Heart, F, Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114 (2006), 1883–1891.
56. Walford, G., Loscalzo, J., Nitric oxide in vascular biology. J. Thromb. Haemost. 1 (2003), 2112–2118.
57. Wang, H., Alencar, A., Lin, M., Sun, X., Sudo, R.T., Zapata-Sudo, G., Lowe, D.A., Groban, L., Activation of GPR30 improves exercise capacity and skeletal muscle strength in senescent female Fischer344 × Brown Norway rats. Biochem. Biophys. Res. Commun. 475 (2016), 81–86.
58. Wang, H., Jessup, J.A., Lin, M.S., Chagas, C., Lindsey, S.H., Groban, L., Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc. Res. 94 (2012), 96–104.
59. Wang, H., Zhao, Z., Lin, M., Groban, L., Activation of GPR30 inhibits cardiac fibroblast proliferation. Mol. Cell. Biochem. 405 (2015), 135–148.
60. Weil, B.R., Manukyan, M.C., Herrmann, J.L., Wang, Y., Abarbanell, A.M., Poynter, J.A., Meldrum, D.R., Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148 (2010), 436–443.
61. Wright, A.F., Ewart, M.A., Mair, K., Nilsen, M., Dempsie, Y., Loughlin, L., Maclean, M.R., Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc. Res. 106 (2015), 206–216.
62. Xu, D., Niu, W., Luo, Y., Zhang, B., Liu, M., Dong, H., Liu, Y., Li, Z., Endogenous estrogen attenuates hypoxia-induced pulmonary hypertension by inhibiting pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cells proliferation. Int. J. Med. Sci. 10 (2013), 771–781.
63. Yang, X.P., Reckelhoff, J.F., Estrogen, hormonal replacement therapy and cardiovascular disease. Curr. Opin. Nephrol. Hypertens. 20 (2011), 133–138.
64. Zapata-Sudo, G., Pontes, L.B., da Silva, J.S., Lima, L.M., Nunes, I.K., Barreiro, E.J., Sudo, R.T., Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. Eur. J. Pharmacol. 690 (2012), 176–182.
65. Zhang, T.T., Cui, B., Dai, D.Z., Su, W., CPU 86017, p-chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Acta Pharmacol. Sin. 26 (2005), 1309–1316.